<DOC>
	<DOCNO>NCT02475135</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics relative bioavailability Emtricitabine ( FTC ) Tenofovir alafenamide ( TAF ) administer fixed-dose combination ( FDC ) darunavir ( DRV ) cobicistat ( COBI ) ( darunavir/cobicistat/emtricitabine/tenofovir alafenamide ( D/C/F/TAF ) relative administration FDC Elvitegravir ( EVG ) COBI ( Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ) , fed condition healthy subject ( Panel 1 ) ; evaluate single-dose pharmacokinetics relative bioavailability DRV , COBI , FTC TAF administer FDC ( D/C/F/TAF ) separate agent ( D+C+FTC/TAF ) , fed condition healthy subject ( Panel 2 ) evaluate impact food ( fast high-fat breakfast ) single-dose pharmacokinetics DRV , COBI , FTC , TAF administer FDC ( D/C/F/TAF ) healthy subject ( Panel 3 ) .</brief_summary>
	<brief_title>Relative Bioavailability Food Effect Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination</brief_title>
	<detailed_description>This Phase 1 , 3-panel , open-label , randomize , 2-way crossover study healthy subject . Healthy subject divide 3 panel ( Panel 1 , 2 3 ) . Subjects randomize within panel . In panel , 2 subsequent session , subject receive 2 treatment ( Treatments A B Panel 1 , Treatments C D Panel 2 , Treatments E F Panel 3 ) . Each treatment define follow : Treatment A : single oral dose D/C/F/TAF 800/150/200/10 milligram ( mg ) FDC tablet fed condition ( standardize regular breakfast ) ; Treatment B : single oral dose E/C/F/TAF 150/150/200/10 mg FDC tablet fed condition ; Treatment C : single oral dose D/C/F/TAF 800/150/200/10 mg FDC tablet fed condition ; Treatment D : single oral dose DRV 800-mg tablet , FTC/TAF 200/10 mg tablet COBI 150 mg tablet feed condition . Treatment E : single oral dose D/C/F/TAF 800/150/200/10 mg FDC tablet , fast condition Treatment F : single oral dose D/C/F/TAF 800/150/200/10 mg tablet , standardize high-fat breakfast . Each treatment separate washout period least 7 day . Primarily pharmacokinetic parameter assess . Subjects ' safety assess throughout .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Subject must nonsmoker least 3 month prior selection Subject must body mass index ( BMI , weight kg divide square height meter ) 18.5 30.0 kg/m^2 , extremes include Subject must healthy basis physical examination , medical history , vital sign , 12lead ECG perform screen . If result outside normal reference range , subject may include list exclusion criterion Investigator judge abnormality deviation normal clinically significant . This determination must record subject 's source document initial Investigator Subject must healthy basis clinical laboratory test perform screen . If result biochemistry panel , hematology , urinalysis outside normal reference range , subject may include abnormality deviation normal list exclusion criterion , Investigator judge clinically significant . This determination must record subject 's source document initial Investigator Subject must willing able adhere prohibition restriction specify protocol Subject positive human immunodeficiency virus1 ( HIV1 ) HIV2 test screening Subject hepatitis A , B , C infection ( confirm positive hepatitis A antibody immunoglobulin M ( IgM ) , hepatitis B surface antigen , and/or hepatitis C virus antibody , respectively ) screen Subject currently significant active diarrhea , nausea , constipation Investigator 's opinion could influence drug absorption bioavailability Subject history renal insufficiency Subject know allergy , hypersensitivity , intolerance DRV , COBI ( GS9350 ) , EVG ( Panel 1 ) , FTC , TAF excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Immunodeficiency Virus Type 1 , Human</keyword>
	<keyword>Immunodeficiency Virus Type 2 , Human</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Cobicistat</keyword>
	<keyword>Tenofovir Alafenamide</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Elvitegravir</keyword>
</DOC>